Business Context and Reporting Period
Company: Schering-Plough Corporation (Note: Input metadata referenced Merck & Co., Inc., but the filing text identifies Schering-Plough Corporation).
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three months ended March 31, 1998
Common Shares Outstanding: 733,667,804 as of March 31, 1998
Key Financial Metrics
| Metric | Q1 1998 | Q1 1997 |
|---|---|---|
| Sales (Revenue) | $1,908 million | $1,568 million |
| Net Income | $450 million | $375 million |
| Income Before Taxes | $596 million | $497 million |
| Operating Cash Flow | $322 million | $189 million |
| Diluted EPS | $0.61 | $0.51 |
| Dividends Per Share | $0.19 | $0.165 |
| Cash and Equivalents (End of Period) | $622 million | $757 million |
| Short-term Debt | $449 million | $581 million |
| Long-term Debt | $46 million | $46 million |
Margins: Income before taxes represented 31.3% of sales in Q1 1998 (vs. 31.7% in Q1 1997). Cost of sales increased to 19.9% of sales (vs. 18.4% in 1997). The effective tax rate was 24.5%.
Material Changes vs. Prior Period
- Revenue Growth: Sales increased 22% ($340 million) year-over-year. Excluding foreign exchange, sales grew 25%. Excluding the June 1997 acquisition of Mallinckrodt's animal health business ($91 million contribution), organic sales grew 16%.
- Profitability: Net income rose 20% to $450 million. Earnings per share increased 20% to $0.61.
- Cash Flow: Operating cash flow improved significantly to $322 million from $189 million. However, net cash decreased by $92 million due to financing activities.
- Debt Reduction: Short-term borrowings were reduced by $128 million during the quarter.
- Shareholder Returns: The company repurchased $34 million of common shares and paid $140 million in dividends.
Guidance, Outlook, Risks, and Unusual Items
Management Commentary and Outlook
- Product Drivers: Growth was led by CLARITIN ($436 million sales), INTRON A, and cardiovascular products (IMDUR, K-DUR). International sales were impacted by currency fluctuations but grew 13% excluding FX.
- Dividend Increase: In April 1998, the Board increased the quarterly dividend by 16% to $0.22 per share.
- Share Repurchase: A $1 billion share repurchase program authorized in October 1997 was approximately 3% complete as of March 31, 1998.
Risks and Contingencies
- Antitrust Litigation: The company is a defendant in over 160 antitrust actions alleging price-fixing and conspiracy. A federal class action was settled for $22 million (payable over three years). State class actions remain pending, with plaintiffs seeking treble damages.
- FTC Investigation: The Federal Trade Commission is investigating potential price-fixing conspiracies involving the company and other pharmaceutical firms. The company denies any wrongdoing.
- Regulatory and Competitive Risks: Management cites risks from government-mandated cost containment, generic competition, patent disputes, and regulatory approval delays.
Investor Verification Checklist
- Antitrust Settlement Status: Verify the payment schedule and finality of the $22 million federal class action settlement and the status of pending state class actions.
- FTC Investigation: Monitor updates regarding the ongoing FTC investigation into prescription drug pricing.
- Organic Growth Sustainability: Assess whether the 16% organic sales growth (excluding Mallinckrodt) is sustainable given the competitive pricing environment in managed care.
- Share Repurchase Progress: Track the execution of the $1 billion share repurchase program, which was only 3% complete at the end of Q1.
- Dividend Policy: Confirm the implementation of the increased quarterly dividend of $0.22 per share.